Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.
about
PTH receptor-1 signalling-mechanistic insights and therapeutic prospectsMinireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulationPharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disordersLigand-specific endocytic dwell times control functional selectivity of the cannabinoid receptor 1Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12Optodynamic simulation of β-adrenergic receptor signalling.Human Luteinizing Hormone and Chorionic Gonadotropin Display Biased Agonism at the LH and LH/CG ReceptorsDevelopment and characterization of pepducins as Gs-biased allosteric agonists.Delineation of a conserved arrestin-biased signaling repertoire in vivo.International Union of Basic and Clinical Pharmacology. XCIII. The parathyroid hormone receptors--family B G protein-coupled receptors.Naturally Occurring Follicle-Stimulating Hormone Glycosylation Variants.Endosomal generation of cAMP in GPCR signaling.Dysregulated Inflammatory Signaling upon Charcot-Marie-Tooth Type 1C Mutation of SIMPLE Protein.The atypical antipsychotics clozapine and olanzapine promote down-regulation and display functional selectivity at human 5-HT7 receptors.Opioid receptors: Structural and mechanistic insights into pharmacology and signaling.Exploring G protein-coupled receptor signaling networks using SILAC-based phosphoproteomicsBinding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling.Agonist-Specific Recruitment of Arrestin Isoforms Differentially Modify Delta Opioid Receptor FunctionMechanisms of Biased β-Arrestin-Mediated Signaling Downstream from the Cannabinoid 1 Receptor.β-arrestin-biased signaling through the β2-adrenergic receptor promotes cardiomyocyte contraction.The conformational signature of β-arrestin2 predicts its trafficking and signalling functions.HDX-MS guided drug discovery: small molecules and biopharmaceuticals.Minireview: Role of intracellular scaffolding proteins in the regulation of endocrine G protein-coupled receptor signaling.Exploiting agonist biased signaling of chemokines to target cancer.The Multiple Waves of Cannabinoid 1 Receptor Signaling.Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets.G Protein-Coupled Receptor Signaling Through β-Arrestin-Dependent Mechanisms.Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.The Diverse Roles of Arrestin Scaffolds in G Protein-Coupled Receptor Signaling.Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased agonism.Biased Gs versus Gq proteins and β-arrestin signaling in the NK1 receptor determined by interactions in the water hydrogen bond networkRegulation of G Protein-Coupled Receptors by Ubiquitination.Ligand-selective activation of heterologously-expressed mammalian olfactory receptor.Modulation of opioid receptor affinity and efficacy via N-substitution of 9β-hydroxy-5-(3-hydroxyphenyl)morphan: Synthesis and computer simulation study.Biased signalling: from simple switches to allosteric microprocessors.Pharmacological Chaperones as Potential Therapeutic Strategies for Misfolded Mutant Vasopressin Receptors.In Vivo and In Vitro Impact of Carbohydrate Variation on Human Follicle-Stimulating Hormone Function.The EphA2 receptor is activated through induction of distinct, ligand-dependent oligomeric structuresMaking Sense of Pharmacology: Inverse Agonism and Functional Selectivity
P2860
Q26798005-CF720207-4D99-4026-A72B-542C5A4A2C8FQ26829111-80258DB9-C0FE-4B8A-B8B6-B60D6043472DQ27006437-54F83D70-7724-4AC4-8085-AACEBB30830DQ28245037-7ED3C988-1E9B-41C3-8A89-7462A8583C6DQ28246158-51B63FF2-39F4-462F-A65E-0083E889783DQ30666240-EFDC8552-B0E6-4C19-8DCA-57F7F79F7D2BQ33680914-38331FAB-9A09-4D36-9662-671ED09DC874Q34774416-E7422B27-BA21-4E5D-ABF6-3246E2B7D518Q35198039-D9992428-EAEE-40C8-AFDB-BFCFDBA8D89EQ35383816-12DBF57D-580E-46B6-9914-99DFAF37ED54Q35438553-87828EA0-1D62-49D4-BCD7-4E4009456961Q35563982-01F48E17-A90C-4F9C-8E93-1C1204125C44Q35764200-B73E8709-FC00-49CF-AC73-93CE4C606587Q35911754-725F2D4A-997F-4576-9895-E4C656653EFBQ36096058-66BA37A1-141B-40D3-94A8-A503ADAFBBAAQ36418560-6A3E550F-81C3-4B17-B87D-0D75E4F2582EQ36431762-43E33B2E-2D8C-47F8-B370-DC88100918BFQ36718661-E860D047-1A33-4F79-8811-44FB0C773B26Q36947742-E2DBEA54-E2AA-4164-BED0-11530BDF7C6EQ37102508-511953CD-1C0E-4914-9941-74F1CACC5635Q37151762-A325FC6C-4140-41D7-A2DF-F2C1E182B3F5Q38245359-2B008109-B89F-4097-86CF-56990B17E88CQ38459674-065A6CB6-FC5E-484C-AA63-AEEFB7B7B96CQ38819497-70321A27-FC1A-4015-A771-DBD174C8BAD3Q38874828-A2B67AF7-9EF7-4FB1-8CB9-3078A03F0108Q39021630-266E6077-C9CC-4CC0-9AD1-74B65A8E15A6Q39193257-F8B4CC21-9352-45F3-9410-BCC24CE161B3Q39319839-1D0D9D62-3325-473F-BD10-8A38C1C6CF05Q39381430-9FD9AC74-67B7-48B9-A7DB-5E4B3BCF7F51Q39397383-0FA16894-AC2E-48E0-84F7-490CE0025050Q41455641-2EAABDF5-3DAE-49B4-AC94-67FABA5E5A25Q42009313-96FE7C1D-4E94-4405-AE03-A15B0B4AA746Q42933983-423D7A0C-E8A5-468C-B513-B3E290D49A68Q44344079-0C92E5A7-C6D0-47F4-A2DD-75076954F99BQ47231111-4496A0FC-C360-4D4E-A39D-48EFE528043EQ47757944-6705BFAC-CD04-45F6-93C8-3952A3D10AA9Q55365511-712ACDDF-7A2C-4222-8A92-EDBB2841AC50Q57147941-1CA4A331-0C51-43A0-BAFE-B5CE5B2B60C7Q58798205-0DB7338C-64D9-404B-9064-3B9BEDF75CD8
P2860
Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.
@en
Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.
@nl
type
label
Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.
@en
Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.
@nl
prefLabel
Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.
@en
Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.
@nl
P2860
P356
P1476
Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery
@en
P2093
Louis M Luttrell
P2860
P304
P356
10.1210/ME.2013-1314
P577
2014-01-16T00:00:00Z